Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844